
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing captopril, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing captopril are listed in tablet form. No finished captopril product of any kind is listed in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Captopril is an ACE inhibitor blood pressure and heart medicine, taken by mouth, that a pharmacy may compound when a prescriber orders it.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor. It blocks the enzyme that makes angiotensin II, a hormone that tightens blood vessels and signals the body to hold on to salt and water, so blood vessels relax and blood pressure falls. Unlike most ACE inhibitors, it does not need to be activated in the body. Manufactured products are generic captopril tablets, indicated for high blood pressure, heart failure, left ventricular dysfunction after a heart attack, and diabetic kidney disease in type 1 diabetes with retinopathy. A published review of extemporaneously prepared liquids describes captopril oral liquids made from tablets for infants and young children. A prescriber might order captopril compounded as a liquid or in a strength that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Captopril labels carry a boxed warning for fetal toxicity: drugs that act on the renin-angiotensin system can injure or kill a developing baby, so stop it as soon as pregnancy is detected and tell your prescriber. Do not use it if you have had a reaction to any ACE inhibitor, including angioedema (swelling of the face, lips, tongue or throat); if you have diabetes and take aliskiren; or within 36 hours of sacubitril/valsartan. Get emergency help for facial or throat swelling. Report fever, sore throat or other signs of infection, which can signal a low white blood cell count. Other warnings include low blood pressure, high potassium, kidney changes and rare liver injury. Tell your prescriber about potassium supplements or salt substitutes, potassium-sparing diuretics, lithium and NSAIDs. Taste changes and a persistent dry cough can occur. Take it one hour before meals. LactMed says the small amounts in breast milk are not expected to harm a breastfed infant; the label advises choosing between nursing and the drug. Talk to your prescriber or pharmacist about side effects.
Captopril is a sulfhydryl-containing ACE inhibitor that is active as given. It reduces angiotensin II and aldosterone and may also slow bradykinin breakdown. Per the label, absorption is rapid with peak levels at about one hour, food reduces absorption by about 30 to 40 percent, minimal average absorption is about 75 percent, protein binding is 25 to 30 percent, and the half-life of unchanged drug is probably less than 2 hours; over 95 percent of absorbed drug is excreted in urine, and captopril is retained in renal impairment. Labeled indications (generic captopril tablets, ANDA): hypertension, heart failure, left ventricular dysfunction after myocardial infarction, and diabetic nephropathy in type 1 diabetes with retinopathy. StatPearls lists acute hypertensive crisis and Raynaud phenomenon as off-label uses; these are not FDA-approved indications. Neutropenia and agranulocytosis risk is highest with renal impairment and collagen vascular disease; the label advises white cell counts before and during treatment in renal impairment. Proteinuria, nephrotic syndrome, rash, dysgeusia, angioedema (including intestinal), cholestatic hepatic failure, and hyperkalemia are labeled. Avoid dual RAS blockade. In aqueous liquids captopril oxidizes to captopril disulfide (Glass and Haywood 2006). Monitor blood pressure, potassium, renal function and white cell counts. Dosing is per prescriber.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally